Syndax [SNDX] vs Capricor [CAPR] Detailed Stock Comparison

Syndax Pharmaceuticals Inc.

NASDAQ
Loading...

Capricor Therapeutics Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Syndax Pharmaceuticals Inc. wins in 6 metrics, Capricor Therapeutics Inc. wins in 10 metrics, with 0 ties. Capricor Therapeutics Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Syndax Pharmaceuticals Inc. Capricor Therapeutics Inc. Better
P/E Ratio (TTM) -6.50 -15.61 Syndax Pharmaceuticals Inc.
Price-to-Book Ratio 28.94 6.62 Capricor Therapeutics Inc.
Debt-to-Equity Ratio 534.48 4.75 Capricor Therapeutics Inc.
PEG Ratio 0.22 -0.05 Syndax Pharmaceuticals Inc.
EV/EBITDA -6.65 -16.23 Syndax Pharmaceuticals Inc.
Profit Margin (TTM) -165.60% 0.00% Capricor Therapeutics Inc.
Operating Margin (TTM) -91.59% 0.00% Capricor Therapeutics Inc.
Return on Equity -161.83% -46.56% Capricor Therapeutics Inc.
Return on Assets (TTM) -27.25% -25.68% Capricor Therapeutics Inc.
Free Cash Flow (TTM) $-323.17M $-81.54M Capricor Therapeutics Inc.
1-Year Return 85.86% 202.93% Capricor Therapeutics Inc.
Price-to-Sales Ratio (TTM) 10.95 N/A N/A
Enterprise Value $1.82B $1.72B Syndax Pharmaceuticals Inc.
EV/Revenue Ratio 10.55 N/A N/A
Gross Profit Margin (TTM) 96.06% N/A N/A
Revenue per Share (TTM) $2 $0 Syndax Pharmaceuticals Inc.
Earnings per Share (Diluted) $-3.29 $-2.26 Capricor Therapeutics Inc.
Beta (Stock Volatility) 0.41 0.48 Syndax Pharmaceuticals Inc.
Short % of Float 26.77% 19.17% Capricor Therapeutics Inc.

Syndax Pharmaceuticals Inc. vs Capricor Therapeutics Inc. Stock Performance Analysis

Loading Price Chart...

SNDX
CAPR

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Syndax Pharmaceuticals Inc.-0.27%-6.48%-8.12%-14.30%-6.95%-13.90%
Capricor Therapeutics Inc.1.10%-5.15%-17.49%6.97%-7.74%-2.37%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Syndax Pharmaceuticals Inc.85.86%-4.30%9.75%48.41%65.32%65.32%
Capricor Therapeutics Inc.202.93%558.46%676.17%-7.24%-90.64%-97.72%

Performance & Financial Health Analysis: Syndax Pharmaceuticals Inc. vs Capricor Therapeutics Inc.

MetricSNDXCAPR
Market Information
Market Cap i$1.89B$2.04B
Market Cap CategorySmall capMid cap
10 Day Avg. Volume i1,421,560987,380
90 Day Avg. Volume i1,499,3771,234,213
Last Close$18.34$27.64
52 Week Range$8.59 - $25.59$4.30 - $40.37
% from 52W High-28.33%-31.53%
All-Time High$29.86 (Jan 30, 2023)$3,500.00 (Oct 22, 2007)
% from All-Time High-38.58%-99.21%
Growth Metrics
Quarterly Revenue Growth7.95%N/A
Quarterly Earnings Growth7.95%-1.00%
Financial Health
Profit Margin (TTM) i-1.66%0.00%
Operating Margin (TTM) i-0.92%0.00%
Return on Equity (TTM) i-1.62%-0.47%
Debt to Equity (MRQ) i534.484.75
Cash & Liquidity
Book Value per Share (MRQ)$0.74$5.33
Cash per Share (MRQ)$4.69$5.53
Operating Cash Flow (TTM) i$-322,980,000$-69,811,264
Levered Free Cash Flow (TTM) i$-210,053,120$-39,600,748
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Syndax Pharmaceuticals Inc. vs Capricor Therapeutics Inc.

MetricSNDX (Apr 26, 2026)CAPR (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i-6.50-15.61
Forward P/E i-42.17-56.73
PEG Ratio i0.22-0.05
Price to Sales (TTM) i10.95N/A
Price to Book (MRQ) i28.946.62
Market Capitalization
Market Capitalization i$1.89B$2.04B
Enterprise Value i$1.82B$1.72B
Enterprise Value Metrics
Enterprise to Revenue i10.55N/A
Enterprise to EBITDA i-6.65-16.23
Risk & Other Metrics
Beta i0.410.48
Book Value per Share (MRQ) i$0.74$5.33

Financial Statements Comparison: Syndax Pharmaceuticals Inc. vs Capricor Therapeutics Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricSNDX (2025)CAPR (2025)
Revenue/Sales i172.35M0
Cost of Goods Sold i6.97MN/A
COGS % of Revenue i4.0%-
Gross Profit i165.38MN/A
Gross Margin i96.0%-
Research & Development i258.78M84.45M
Operating Income (EBIT) i-273.08M-108.14M
Operating Margin i-158.4%-
EBITDA i-251.63M-106.21M
EBITDA Margin i-146.0%-
Pre-Tax Income i-285.42M-105.04M
Pre-Tax Income % of Revenue i-165.6%-
Income Tax iN/A1,600
Income Tax % of Revenue i0.0%-
Net Income (Profit) i-285.42M-105.04M
Profit Margin i-165.6%-

Balance Sheet & Liquidity Metrics

MetricSNDX (2025)CAPR (2025)
Cash & Equivalents i134.93M287.85M
Total Current Assets i528.08M322.94M
Total Current Assets % of Revenue i306.4%-
Total Current Liabilities i120.12M35.84M
Total Current Liabilities % of Revenue i69.7%-
Long-Term Debt i344.96M14.32M
Long-Term Debt % of Revenue i200.1%-
Total Shareholders Equity i64.63M305.79M
Retained Earnings i-1.51B-304.88M
Retained Earnings % of Revenue i-874.1%-
Property, Plant & Equipment i1.61M22.27M

Cash Flow Statement Comparison

MetricSNDX (2025)CAPR (2025)
Operating Cash Flow i-343.52M-71.86M
Operating Cash Flow % of Revenue i-199.3%-
Capital Expenditures i-187,000-11.72M
Free Cash Flow i-323.17M-81.54M
FCF Margin i-187.5%-
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricSNDXCAPR
Shares Short i20.97M10.04M
Short Ratio i14.277.73
Short % of Float i26.77%19.17%
Shares Outstanding i87.41M57.37M
Float Shares i74.69M48.61M
% Held by Insiders i1.81%9.47%
% Held by Institutions i116.48%53.91%
% Held by Public i-18.29%36.62%

Dividend Analysis & Yield Comparison: Syndax Pharmaceuticals Inc. vs Capricor Therapeutics Inc.

MetricSNDXCAPR
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A